New cures for hepatitis C — but are they affordable?
The public health burden of hepatitis C is enormous. This serious viral infection of the liver causes cirrhosis, liver cancer, and end-stage liver failure, often requiring liver transplantation. Over 3 million people in the United States, and 150 million worldwide, are infected with hepatitis C virus, resulting in 700,000 deaths per year. People who are infected with hepatitis C virus often have no symptoms. The virus persists in the liver, slowly damaging liver tissue over a long period of time. For this reason, it is critical that progression of liver damage be stopped before advanced liver disease or liver cancer occurs...
Source: New Harvard Health Information - January 7, 2016 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Drugs and Supplements Health Health care Infectious diseases hepatitis C Source Type: news

Combo Tx Benefits Biliary Cirrhosis Pts Failing Ursodeoxycholic Acid (CME/CE)
(MedPage Today) -- Adding bezafibrate boosts responses, meta-analysis suggests (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 27, 2015 Category: Gastroenterology Source Type: news

CDC finds US alcohol poisoning and cirrhosis 'deaths hit record high'
The Centers for Disease Control and Prevention revealed that more than 30,700 people in the US died in 2014 because of alcohol-induced causes - a 37 per cent increase from 2002. (Source: the Mail online | Health)
Source: the Mail online | Health - December 24, 2015 Category: Consumer Health News Source Type: news

Potential treatment for cirrhosis discovered by scientists
Cirrhosis is the main risk factor for liver cancer. The same target may be the key to preventing and treating this condition, suggests researchers at the conclusion of a recent study. Cirrhosis is among the top 20 causes of death from disease worldwide. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 11, 2015 Category: Science Source Type: news

Scientists in Barcelona discover a potential treatment for cirrhosis
(Institute for Research in Biomedicine (IRB Barcelona)) Cirrhosis is the main risk factor for liver cancer. The same target may be the key to preventing and treating this condition.Cirrhosis figures among the top 20 causes of death from disease worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2015 Category: Global & Universal Source Type: news

FibroScan Measures Liver Disease
BALTIMORE. (Ivanhoe Newswire) – Thirty million Americans, or one in 10, have some form of liver disease. It could be scarring from a hepatitis C infection, cirrhosis or even liver (Source: Medical Headlines From Ivanhoe.com)
Source: Medical Headlines From Ivanhoe.com - December 8, 2015 Category: Consumer Health News Source Type: news

Daclatasvir, Sofosbuvir, Ribavirin Effective in Hep C Type 3Daclatasvir, Sofosbuvir, Ribavirin Effective in Hep C Type 3
The combination is effective in most patients with hepatitis C genotype 3 infection and cirrhosis, results from the ALLY-3+ trial show. Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 20, 2015 Category: Infectious Diseases Tags: Gastroenterology News Source Type: news

Short-Course Triple HCV Tx Has Promise in Cirrhosis
(MedPage Today) -- Harvoni plus vedroprevir for 8 weeks achieved high SVR rates (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 19, 2015 Category: Gastroenterology Source Type: news

HCV Patients With Cirrhosis Respond Well to Combo Tx (CME/CE)
(MedPage Today) -- Sofosbuvir-velpatasvir appears optimal when paired with ribavirin (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 17, 2015 Category: Primary Care Source Type: news

Viekira Pak Results Reassuring for Compensated CirrhosisViekira Pak Results Reassuring for Compensated Cirrhosis
For patients with genotype 1 hepatitis C infection and cirrhosis, the combination of ombitasvir, paritaprevir, and ritonavir plus dasabuvir, with or without ribavirin, is safe and effective. Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 17, 2015 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting®
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patien...
Source: Merck.com - Research and Development News - November 15, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hep C Hepatitis C MSD NYSE:MRK Source Type: news

Occult Cirrhosis Diagnosed by Transient ElastographyOccult Cirrhosis Diagnosed by Transient Elastography
Occult cirrhosis is often an under-monitored disease. Could transient elastography help clinicians to both better understand and properly diagnose the condition? Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Middle-Aged White Americans Are Dying More Than They Should Be
Middle-aged white Americans are dying at increasing rates and half a million people are dead who should not be, according to a new report published in the Proceedings of the National Academy of Sciences. The study, co-authored by Anne Case and Angus Deaton, analyzed death rates for men and women aged 45 to 54 in the United States, a range often categorized as "middle-age." The duo, both economics professors at Princeton, then compared the data to those death rates found within other domestic racial categories and those seen in similarly wealthy nations. Black, Hispanic and older Americans (65 and up) have continu...
Source: Science - The Huffington Post - November 3, 2015 Category: Science Source Type: news

Diabetes, Hypertension Up Risk of Liver Cancer (CME/CE)
(MedPage Today) -- Link to hepatocellular carcinoma is independent of cirrhosis, say researchers (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 23, 2015 Category: Cardiology Source Type: news

Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury
Cases of hepatic decompensation and liver failure in patients with underlying liver cirrhosis who were taking these medicines. (Source: FDA MedWatch)
Source: FDA MedWatch - October 22, 2015 Category: American Health Source Type: news

Alcohol Policies and Alcoholic Cirrhosis Mortality in the United States
(Source: CDC Preventing Chronic Disease)
Source: CDC Preventing Chronic Disease - October 16, 2015 Category: Global & Universal Source Type: news

Tough Alcohol Policies Linked to Lower Death Rates from Liver Damage
Findings dovetail with prior research that has shown tighter rules associated with less binge drinking Source: HealthDay Related MedlinePlus Pages: Alcoholism and Alcohol Abuse, Cirrhosis, Liver Diseases (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 15, 2015 Category: Consumer Health News Source Type: news

One-year mortality after traumatic brain injury in liver cirrhosis patients-a ten-year population-based study - Cheng CY, Ho CH, Wang CC, Liang FW, Wang JJ, Chio CC, Chang CH, Kuo JR.
This study investigated the 1-year mortality of patients who underwent brain surgery following traumatic brain injury (TBI) who also had alcoholic and/or nonalcoholic liver cirrhosis (LC) using a nationwide database in Taiwan. A longitudinal cohort study m... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - October 13, 2015 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Fatty liver disease and scarring have strong genetic component
Hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 1, 2015 Category: Science Source Type: news

Fatty liver disease and scarring have strong genetic component
(University of California - San Diego) Researchers at the University of California, San Diego School of Medicine say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - October 1, 2015 Category: Global & Universal Source Type: news

Liver Cirrhosis Treatment May Curb Cerebral EdemaLiver Cirrhosis Treatment May Curb Cerebral Edema
Lactulose and rifaximin treatment of cirrhosis patients with minimal hepatic encephalopathy (MHE) reverses low-grade cerebral edema, according to researchers from India. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 29, 2015 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
New interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan, genotype 1 chronic hepatitis C, including those with compensated cirrhosis[1] VIEKIRAX consists of a 12-week, two direct-acting antiviral, fixed... Biopharmaceuticals, RegulatoryAbbVie, VIEKIRAX, ombitasvir, paritaprevir, ritonavir (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2015 Category: Pharmaceuticals Source Type: news

Treatment of Chronic HCV in Patients With CirrhosisTreatment of Chronic HCV in Patients With Cirrhosis
How safe and effective is treatment with sofosbuvir and simeprevir in HCV patients with cirrhosis and contraindications to interferon and/or ribavirin? The American Journal of Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Alcoholic Liver Disease: Types, Symptoms & Treatment
Alcoholic liver disease happens following years of heavy drinking. The heavy drinking might be each day, or a few days a week - such as on weekends. Any type of alcohol may cause disease. Alcohol can cause inflammation of a person's liver. Over a period of time, scarring and cirrhosis may happen. Cirrhosis is the final phase of alcoholic liver disease. (Source: Disabled World)
Source: Disabled World - September 27, 2015 Category: Disability Tags: Health and Disability Source Type: news

Alcohol use and binge drinking among women of childbearing age - United States, 2011-2013 - Tan CH, Denny CH, Cheal NE, Sniezek JE, Kanny D.
Excessive alcohol use* is risk factor for a wide range of health and social problems including liver cirrhosis, certain cancers, depression, motor vehicle crashes, and violence. Alcohol use during pregnancy can lead to fetal alcohol spectrum disorders (... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - September 26, 2015 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Nutritional Therapy in Cirrhosis or Alcoholic HepatitisNutritional Therapy in Cirrhosis or Alcoholic Hepatitis
Many patients with liver disease, including cirrhosis and alcoholic hepatitis, are malnourished. Could nutritional therapy help these patients and also reduce mortality risk? Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 25, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

What We Talk About When We Talk About Hepatitis C
Since 2007, more people have died every year from hepatitis C than from HIV. Fortunately, the latest hepatitis C medications can cure nearly everyone in a relatively quick, easy fashion. So, if it is so easy to cure hepatitis C, why haven't we? Ostensibly, it is because of the cost. At $1125 a pill for Gilead Sciences' drug Harvoni, a 12-week course of hepatitis C treatment would amount to $94,500. Trying to manage these costs, many state Medicaid programs and insurance companies have severely restricted access to treatment. You save money if you deny treatment to people, and dead people cost nothing. This means that al...
Source: Healthy Living - The Huffington Post - September 17, 2015 Category: Consumer Health News Source Type: news

New Scoring System Predicts Transplant-Free Survival in PBC (CME/CE)
(MedPage Today) -- GLOBE outperforms other criteria as prognosticator in primary biliary cirrhosis (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 15, 2015 Category: Gastroenterology Source Type: news

Study finds North-South divide in UK life expectancy
ConclusionThis study used data to analyse the burden of disease and injury in England, and within each English region by level of deprivation. This was compared with the remaining constituent countries of the UK and with other comparable countries.The researchers found an overall increase in life expectancy from 1990 to 2013. The decreased mortality gap between men and women is also encouraging. However, the inequality of life expectancy across regions of England has not improved. Those in more deprived areas have not yet reached the life expectancy of the less deprived in 1990. Despite the overall decline in mortality, th...
Source: NHS News Feed - September 15, 2015 Category: Consumer Health News Tags: Heart/lungs Lifestyle/exercise Cancer Older people Source Type: news

Medical News Today: Outreach invitations boost HCC screening in cirrhosis patients
New research presented at a conference in Paris suggests outreach interventions may increase screening for hepatocellular carcinoma in patients with cirrhosis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 15, 2015 Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news

Updated label for Daklinza for the treatment of chronic hepatitis C genotype 3 approved by the EC
Daklinza in combination with sofosbuvir is the first 12-week all-oral therapy for genotype 3 patients without cirrhosis in Europe (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 14, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Pharmacogenetics Legislation & regulation Hepatic disorders Patient care ALLY-3 cirrhosis combination daklinza genotype 3 chronic hepatitis C hcv Latest News ribaviri Source Type: news

Cirrhosis, antibodies increase risk of poor outcome for autoimmune hepatitis patients
New research reports that cirrhosis at first diagnosis and antibodies for the soluble liver antigen/liver pancreas antigen (SLA/LP) are major risk factors for poor short- and long-term outcome in patients with autoimmune hepatitis. Scientists also found that patients diagnosed in childhood were at higher risk of relapse, need of a liver transplant, and reduced life expectancy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 1, 2015 Category: Science Source Type: news

Cirrhosis, antibodies increase risk of poor outcome for autoimmune hepatitis patients
(Wiley) New research reports that cirrhosis at first diagnosis and antibodies for the soluble liver antigen/liver pancreas antigen are major risk factors for poor short- and long-term outcome in patients with autoimmune hepatitis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2015 Category: Global & Universal Source Type: news

FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
NEW YORK, Aug. 31, 2015 -- (Healthcare Sales & Marketing Network) -- Intercept Pharmaceuticals, Inc. (ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic unde... Biopharmaceuticals, FDAIntercept Pharmaceuticals, obeticholic acid, cirrhosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 31, 2015 Category: Pharmaceuticals Source Type: news

Mechanisms of Non-response to Hepatitis C TherapyMechanisms of Non-response to Hepatitis C Therapy
How does cirrhosis affect the response to antiviral therapy in patients with hepatitis C? Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Liver Damage from Hepatitis C More Widespread Than Thought
If left undetected, it can lead to liver failure and even death, study authors note Source: HealthDay Related MedlinePlus Pages: Cirrhosis, Hepatitis C (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 27, 2015 Category: Consumer Health News Source Type: news

Chemokines CCL4, CCL5 May Be Associated With Liver Cancer in Cirrhotic PatientsChemokines CCL4, CCL5 May Be Associated With Liver Cancer in Cirrhotic Patients
High serum levels of the inflammatory chemokines CCL4 and CCL5 in patients with cirrhosis may be an indication of hepatocellular cancer (HCC), report researchers from Germany. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 21, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cirrhosis Underdiagnosed and Underdocumented in Patients With Hepatitis CCirrhosis Underdiagnosed and Underdocumented in Patients With Hepatitis C
The prevalence of cirrhosis in patients with chronic hepatitis C infection may be as much as four times higher than previously estimated, according to a recent cohort study. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 13, 2015 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Medical News Today: Breath test for early-stage liver disease steps closer
A noninvasive test that analyses levels of limonene in the breath shows promise as a way to detect the early stages of liver cirrhosis, say researchers. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 12, 2015 Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news

New breath test shows possible biomarker for early-stage liver disease diagnosis
A natural compound called limonene, which is found in oranges and lemons, could be indicative in early-stage diagnosis of liver disease, according to new research. Patients with this illness do not often present with symptoms until the disease is advanced. Even then diagnosis is difficult and the symptoms and signs are often general and can be mistaken for other pathologies. For advanced cirrhosis liver, transplant is the only treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 11, 2015 Category: Science Source Type: news

Genus : the Pink Bacterium—a Case Report
We describe a 58-year-old male with a history of cirrhosis secondary to alcoholic hepatitis who had blood cultures positive for Roseomonas gilardii and responded favorably to therapy with a fluoroquinolone antibiotic. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - August 4, 2015 Category: Microbiology Authors: Roger Nehaul, Ashley H. Davis-Yadley, Shreya Narayanan, John T. Sinnot Tags: Case Report Source Type: news

7 Numbers That Show The Fight Against Hepatitis Is Far From Over
July 28 is World Hepatitis Day, a sorely-needed awareness campaign for diseases that affect more than 400 million people alive today. In the U.S., more people die from hepatitis C than they do from HIV/AIDS. And despite being preventable with vaccine, hepatitis B causes an estimated 1 million deaths every year and is the leading cause of liver cancer worldwide. Despite these shocking numbers, the virus is little understood and discussed, and that’s got to change, according to Dr. H. Nina Kim, director of the Madison HIV/Hepatitis Coinfection Clinic in Washington. “In some ways, the HIV epidemic is tie...
Source: Science - The Huffington Post - July 28, 2015 Category: Science Source Type: news

Good news for people suffering from fatty liver disease: Resistance training can help
Approximately 30% of the population suffer from fatty liver disease, the most common liver disease in the Western world. The disease can lead to inflammation and cirrhosis of the liver. A new study has found that gym training, and not only aerobic exercises, can help reduce liver fat (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 27, 2015 Category: Science Source Type: news

Interferon-Free Treatment for HCV Genotype 4 Approved (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD The FDA has approved a ombitasvir/paritaprevir/ritonavir tablet (marketed as Technivie) for treating hepatitis C virus genotype 4 in patients without cirrhosis or scarring. The … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 27, 2015 Category: Primary Care Source Type: news

FDA approves Technivie for treatment of chronic hepatitis C genotype 4
The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis). (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 24, 2015 Category: American Health Source Type: news

Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - June 29, 2015 Category: Pharmaceuticals Source Type: news

Primary Biliary Cirrhosis
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 25, 2015 Category: Journals (General) Source Type: news

New book on The Hepatitis B and Delta Viruses from CSHLPress
(Cold Spring Harbor Laboratory) The Hepatitis B and Delta Viruses, from CSHLPress, examines all aspects of HBV and HDV infections and their management. Contributors discuss the HBV and HDV life cycles, their unique characteristics (e.g., the formation of HBV cccDNA), the immune responses they elicit, and the challenges they present to the development of antiviral treatments. The molecular mechanisms that lead to liver cirrhosis and hepatocellular carcinoma are reviewed, as are factors that influence the severity of the disease. Conventional treatments are also described. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 18, 2015 Category: Global & Universal Source Type: news

Call to extend hepatitis C drugs access after £190m funding boost
A charity has called for NHS England to allow all hepatitis C patients to access new treatments. It comes after the arm’s length body announced a much delayed commissioning policy for cirrhosis. (Source: HSJ)
Source: HSJ - June 17, 2015 Category: UK Health Source Type: news

XTuit Pharmaceuticals Closes $22 Million Series A Financing to Advance Novel Microenvironmental Modulators for Cancers and Fibrotic Disorders
Funding to Support Early Clinical Proof-of-Concept for Lead Products for Immuno-Oncology and Liver Cirrhosis/Nonalcoholic Steatohepatitis (NASH) Round led by New Enterprise Associates and joined by syndicate including founding investor Polaris Partners ... Biopharmaceuticals, Oncology, Venture CapitalXTuit Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 11, 2015 Category: Pharmaceuticals Source Type: news